|
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Overall, my presentation on what the mRNA industry can learn from the artist Picasso singled out a few specific areas from which I felt our industry could garner greater inspiration and operational prowess. | |
|
|
|
Here, former FDA reviewer Tiffany Lucas shares some of the missteps companies can make when first approaching the FDA with their IND. CureVac’s Ulrike Jägle furthers the discussion, offering a critical best practice she and her colleagues rely upon to streamline their regulatory interactions. |
|
|
|
By Peter H. Calcott, Calcott Consulting LLC | The U.K.'s MHRA has followed through on its promise to issue guidances to aid industry in understanding the recent changes to regulations for licensure of medicines employing cell and gene therapy technology. | |
|
|
|
|
|
| What Is Causing Limited Bioavailability | Video | Aliri Bioanalysis | Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development. |
|
|
|
|
| Solutions For CQA Analysis Of IVT mRNA-Based Biotherapeutics | Application Note | Agilent Technologies | Discover new innovative solutions for mRNA analysis, enhancing accuracy and efficiency in IVT mRNA workflows, including advanced technologies and methodologies to optimize your research and development processes. |
|
|
|
| RNA Leaders USA Congress | The RNA Leaders series explores scientific, clinical, and commercial advancements in RNA medicines, including RNAi, antisense, and mRNA therapies. This September, the 4th USA edition returns to the East Coast, welcoming 350+ attendees across oligos, mRNA and next-gen RNA streams. Join biotech leaders, discovery innovators, delivery developers, manufacturers, pharma, and investors at this exclusive forum for senior RNA experts advancing RNA-based therapies. |
|
|
.png){kind=logo}
